RxDoctor Payments Data

Daniel Drennan, MD

Pain Medicine · Golden, CONPI 1932387966

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Boston Scientific at 57.4% of the total. That places this record below the midpoint for pain medicine clinicians in CO, where the typical reported total is $2,943.

$1,721in general payments, 2019–2025

Across 63 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$988
  • Abbott$201
  • AbbVie$131
  • Vertex$58
  • Pfizer$55
  • Biohaven Pharmaceuticals, Inc.$53
  • plus $235 from 9 others

What the payments were for

  • Food & beverage$1,721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,721 in reported general payments places this provider in the 40th percentile of 96 pain medicine providers in Colorado.

See all pain medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$535,531
Medicare patients
198
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl28$17,741
Buprenorphine57$16,314
Xtampza ErOxycodone Myristate14$8,861
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen84$2,839
Gabapentin79$1,962
Buprenorphine Hcl45$1,842
Oxycodone Hcl97$1,769
Baclofen153$1,224
Duloxetine Hcl23$1,154
Morphine Sulfate ErMorphine Sulfate34$1,139
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$1,009
Tramadol Hcl ErTramadol Hcl11$879
Lidocaine12$758
Pregabalin29$531
Morphine Sulfate14$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$13$26,60242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 96 pain medicine providers in Colorado.

Other pain medicine in Golden

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →